PainTrek

The University of Michigan

About this app

PainTrek is an awarded 3D mobile application initially developed by the Headache & Orofacial Pain Effort (H.O.P.E.) laboratory at the University of Michigan. It allows patients, clinicians, and researchers to track, display and analyze body pain, signs and symptoms (e.g., pain area/intensity, sleep disorders, sensitivity to light, fatigue) from multiple regions, including head, face, and intraoral, in multivector-rotational 3D body with zoom capabilities. This unique PainTrek geographic capability facilitates the precise mapping and analysis of pain across the body with neuroanatomical coordinates, like a Google Map of your health for you and your kids.

PainTrek’s most advanced 3D tools to track, identify, analyze, share and take control of your pain and related symptoms:
- 3D tracking of your migraine/pain and related symptoms across your body, with zoom capabilities
- Analyze your pain and symptoms by region or full body, especially helpful for patients with multiple pain disorders
- Interchangeable 3D bodies that represent diverse age and gender groups, for you and your family
- Longitudinal precise record and analysis of pain, symptoms, and treatment across time
- Customizable choice of migraine and pain-related symptoms, signs, and triggers that you can pick or eliminate as you need
- Pain measures that are validated by multiple clinical pain trials and brain science
- Shareable printable and 3D video reports for clinicians, family members, and researchers
- Light and dark screen modes for patients with light sensitivity (e.g., migraine photophobia)
- Weather data tracking enabled.

PainTrek team working to advance pain research, education, and treatment:
- Artificial Intelligence (AI) enabled technology to help provide in the future feedback to patients and the research community using high privacy regulations
- Used in multiple pain clinical trials and brain studies, including migraine, neuropathic pain, fibromyalgia, cancer pain, visceral pain, sickle cell disease, and TMD.
- Based on cutting-edge migraine/pain research supported by the University of Michigan, National Institute of Health, foundations, and leading world pharma
- Frequent communication and collaboration with multiple pain foundations
- Technology already tested by more than 15,000 pain patients in the US and beyond before the current release.